prednisolone acetate ophthalmic suspension / Generic mfg. - LARVOL DELTA

DVS: Dropless Pars Plana Vitrectomy Study (clinicaltrials.gov) - P4 | N=168 | Completed | Sponsor: Massachusetts Eye and Ear Infirmary | Recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Aug 2026

Trial completion • Trial completion date • Retinal Disorders

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (clinicaltrials.gov) - P1/2 | N=20 | Enrolling by invitation | Sponsor: Maanasa Indaram, MD | Trial completion date: Dec 2026 ➔ Jul 2027 | Trial primary completion date: Aug 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Ophthalmology

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (clinicaltrials.gov) - P2 | N=108 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2027 ➔ Feb 2027 | Trial primary completion date: Jun 2026 ➔ Feb 2027

Enrollment closed • Platinum resistant • Platinum sensitive • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • FOLR1

OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P3 | N=904 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (clinicaltrials.gov) - P1/2 | N=20 | Enrolling by invitation | Sponsor: Maanasa Indaram, MD | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Ophthalmology

OLYMPIA-1: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (clinicaltrials.gov) - P3 | N=822 | Recruiting | Sponsor: Regeneron Pharmaceuticals | N=462 ➔ 822 | Trial completion date: Nov 2031 ➔ Nov 2029 | Active, not recruiting ➔ Recruiting

Enrollment change • Enrollment open • Trial completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

IMGN853-0425: A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube cancers (clinicaltrialsregister.eu) - P1/2 | N=37 | Recruiting | Sponsor: AbbVie Deutschland GmbH & Co. KG

New P1/2 trial • Platinum resistant • Fallopian Tube Cancer • Hepatology • Oncology • Solid Tumor • FOLR1

OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P3 | N=904 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Trial completion date: Apr 2029 ➔ Sep 2029

Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Dextenza in the Post-op Management of Vitreoretinal Surgeries (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: The Cleveland Clinic | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Dec 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Inflammation • Ocular Inflammation • Pain

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Jun 2028 | Suspended ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

OLYMPIA-1: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma (clinicaltrials.gov) - P3 | N=462 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2029 ➔ Nov 2031 | Trial primary completion date: Apr 2029 ➔ Feb 2028

Enrollment closed • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Suspended | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

OLYMPIA-2: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (clinicaltrials.gov) - P3 | N=733 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Lejla Vajzovic, MD, FASRS | N=30 ➔ 16 | Recruiting ➔ Completed

Enrollment change • Trial completion • Anesthesia • Pediatrics • Retinal Disorders

DVS: Dropless Pars Plana Vitrectomy Study (clinicaltrials.gov) - P4 | N=168 | Recruiting | Sponsor: Massachusetts Eye and Ear Infirmary | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Retinal Disorders

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (clinicaltrials.gov) - P1/2 | N=20 | Enrolling by invitation | Sponsor: Maanasa Indaram, MD | Trial completion date: Dec 2024 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Ophthalmology

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Shanghai BDgene Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Mar 2026

Enrollment closed • Trial completion date • Herpes Simplex • Keratitis • Ocular Inflammation • Ophthalmology

OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P3 | N=904 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2028 ➔ Apr 2029 | Trial primary completion date: Sep 2028 ➔ Mar 2028

Enrollment closed • Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=89 | Completed | Sponsor: VivaVision Biotech, Inc | Terminated ➔ Completed

Trial completion • Ocular Inflammation • Ophthalmology • Uveitis

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=89 | Terminated | Sponsor: VivaVision Biotech, Inc | Trial completion date: Mar 2025 ➔ Dec 2024 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ Dec 2024

Trial completion date • Trial primary completion date • Trial termination • Ocular Inflammation • Ophthalmology • Uveitis

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Lejla Vajzovic, MD, FASRS | Trial completion date: Apr 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Anesthesia • Pediatrics • Retinal Disorders

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC. (clinicaltrials.gov) - P1/2 | N=94 | Recruiting | Sponsor: Inder Paul Singh, M.D.

New P1/2 trial • Surgery • Cataract • Ophthalmology

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: VivaVision Biotech, Inc

New P2 trial • Ocular Inflammation • Ophthalmology • Uveitis

CLOSE-3: Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Salvat | Trial completion date: Aug 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2025

Surgery • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics

Dextenza in the Post-op Management of Vitreoretinal Surgeries (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: The Cleveland Clinic | Enrolling by invitation ➔ Recruiting | Trial completion date: Jun 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment status • Surgery • Trial completion date • Trial primary completion date • Inflammation • Ocular Inflammation • Pain